TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01771406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: 8 weeks of CPAP treatment
Study: NCT02091167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
Study: NCT02090907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00903838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pardoprunox
Description: 1.5 to 12 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: 0.75-4.5 mg/day
Study: NCT00704145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taxus Libertè™ paclitaxel drug-eluting stent
Description: device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
Study: NCT01016834

Intervention type: DEVICE
Group type: OTHER
Intervention: Sumavel DosePro
Description: Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration

Intervention type: DRUG
Group type: OTHER
Intervention: Sumatriptan
Description: subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
Study: NCT05433883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleep surgery
Description: Thirty severe OSA patients (AHI\>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.
Study: NCT05958979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes
Study: NCT03859427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Twice weekly IV over 10 minutes on day 1, 2, 8, 9, 15 and 16 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 27 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
Study: NCT01259661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A longitudinal intervention
Description: In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A longitudinal intervention
Description: In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
Study: NCT04519632

Intervention type: OTHER
Intervention: Qualitative study
Description: Qualitative interviews

Intervention type: OTHER
Intervention: Qualitative study
Description: Qualitative interviews

Intervention type: OTHER
Intervention: Qualitative study
Description: Qualitative interviews
Study: NCT05958979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes
Study: NCT04089150

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy (SBRT)
Description: 40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: * Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: * Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Nab-paclitaxel
Description: * Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Nab-paclitaxel
Description: * Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Capecitabine
Description: * Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Capecitabine
Description: * Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatoduodenectomy (Whipple procedure)
Description: R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatoduodenectomy (Whipple procedure)
Description: R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
Study: NCT04924738

Intervention type: BEHAVIORAL
Intervention: Monitoring and lifestyle
Description: Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
Study: NCT03253666

Intervention type: OTHER
Intervention: Nutrient Intake
Description: Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
Study: NCT02556710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of AMPION™
Description: 4 mL Injection of Ampion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL injection of Placebo
Description: 4 mL Injection of Placebo
Study: NCT03985553

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parenting Self-Management Program
Study: NCT03142295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urine transfusion
Description: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
Study: NCT02929576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
Study: NCT02929576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
Study: NCT00991302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAP-IT
Description: Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
Study: NCT04124549

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care with sham intervention
Description: Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 HD hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic Combined Exercise
Description: Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Patients were asked to perform aerobic exercise 20-min and resistance exercise 10-min in the first stage. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE. In the following stages, aerobic exercise was continued 15-min for the second stage, 10-min for the third and the forth stage, 15-min for the fifth stage and 20-min for the last stage. And the time for resistance exercise was adjusted for the total exercise time. The resistance of exercise also progressive increased in order to adapt the target RPE. It was accessible to patients of different ages, gender, cultures and ethnicities.
Study: NCT04516161

Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
Study: NCT03859427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
Study: NCT03370341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active anodal tDCS
Description: active anodal tDCS with behavioral tasks to assess IA

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: active anodal tDCS
Description: active anodal tDCS with behavioral tasks to assess IA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: sham tDCS with behavioral tasks to assess IA

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS with behavioral tasks to assess IA
Study: NCT01636141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OLT1177 Gel
Description: OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
Study: NCT03859427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
Study: NCT02696343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NTrainer
Description: pulsed orocutaneous stimulation paired with tube feedings
Study: NCT01636141

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study: NCT02904252

Intervention type: OTHER
Intervention: Transient elastography
Description: Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F\>2).
Study: NCT01099124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: polyethylene glycol rh recombinant endostatin
Study: NCT01072487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capnography
Description: Monitoring of the capnography curve for early detection of apnea
Study: NCT05905185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction vitamin E (TRF)
Description: The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg of Placebo
Study: NCT04866394

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will be planned with the aim of delivering 30 Gy in 5 fractions.
Study: NCT02381392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein AV400
Description: This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
Study: NCT01534390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)
Description: use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
Study: NCT02696343

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM blind pacifier
Description: regular green Soothie pacifier paired with tube feedings
Study: NCT01808066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Groundskeeper
Description: Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
Study: NCT01483703

Intervention type: DEVICE
Intervention: Laser Speckle Imaging
Description: Laser Speckle Imaging of Critical Care Neonates
Study: NCT02312752

Intervention type: DEVICE
Group type: OTHER
Intervention: Intra-epidermal stimulation electrode
Description: A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds.
Study: NCT02563340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BM-MSCs
Description: BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)
Description: At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)
Description: At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
Study: NCT02520024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-directed care
Study: NCT04962269

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model